Metacef-TC Injection is a potent combination antibiotic formulation containing Ceftazidime 1000 mg and Tobramycin 120 mg, designed for the treatment of serious bacterial infections caused by susceptible organisms. Ceftazidime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, particularly effective against Gram-negative pathogens including Pseudomonas aeruginosa. Tobramycin, an aminoglycoside antibiotic, complements this action by binding to the 30S ribosomal subunit, disrupting protein synthesis and exerting a synergistic effect against resistant strains. Metacef-TC Injection is indicated for severe infections such as lower respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, skin and soft tissue infections, and bone and joint infections where polymicrobial or resistant organisms are suspected. The combination enhances antimicrobial efficacy and reduces the likelihood of resistance development. Administration is typically parenteral, with dosing individualized based on infection severity, patient renal function, and clinical response. Caution is advised in patients with renal impairment, and monitoring of renal function and auditory capacity is recommended due to the nephrotoxic and ototoxic potential of aminoglycosides. Metacef-TC Injection should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize adverse effects.